南财智讯12月18日电，白云山（00874.HK）发布须予披露交易公告，于2025年12月17日，公司子公司 广州医药股份有限公司与浙江海正药业股份有限公司订立《股权交易合同》，拟通过公开挂牌方式收购 浙江省医药工业有限公司100%股权，交易对价为人民币5.005亿元。其中8600万元已作为竞买保证金支 付并转为部分对价，剩余4.145亿元将在合同生效后五个工作日内一次性支付至台州市产权交易所有限 公司指定账户。本次交易构成白云山的须予披露交易，但未达到股东批准标准。目标公司为浙江省排名 前六的优质医药流通企业，最近一年销售收入超40亿元，收购有助于广州医药完善华东区域布局，提升 终端市场覆盖能力。本次收购资金来源于广州医药自有资金，董事会认为交易条款公平合理，不会对公 司财务及经营状况产生不利影响，符合公司及股东整体利益。 ...

Group 1: Major Asset Restructuring - Pulutong plans to acquire 100% of Leqee Group Limited and 8.26% of Hangzhou Lemai through share issuance and cash payment, with the transaction price yet to be determined [2][3] - Wanlong Optoelectronics intends to acquire 100% of Zhejiang Zhongkong Information Industry Co., Ltd. through share issuance and cash payment, with the final transaction price still pending [4][5] - Fengxing Co. plans to acquire 75% of Baiyin Huaxin Jiuhe Recycling Resources Co., Ltd. through share issuance and cash payment, with the asset valuation and transaction price yet to be confirmed [6] Group 2: Corporate Mergers and Acquisitions - CICC disclosed a plan to absorb and merge Dongxing Securities and Xinda Securities, with the merger expected to result in the cancellation of the latter's listings [7] - Meike Home is in the process of planning to acquire control of Shenzhen Wandelong Optoelectronics Co., Ltd., with the valuation still under consideration [8] Group 3: Significant Contracts and Agreements - China CRRC signed several major contracts totaling approximately 533.1 billion yuan, which includes contracts for wind power equipment and urban rail vehicles [15] - China Duty Free Group won bids for duty-free store projects at Shanghai Pudong and Hongqiao International Airports, with a joint investment of 102 million yuan for a new duty-free joint venture [16]

Major Events - CICC (03908) plans a stock swap to absorb Dongxing Securities (601198.SH) and Xinda Securities (601059.SH), with resumption of trading on December 18 [1] - Yuanda Pharmaceutical (00512) has received approval to conduct clinical research in the U.S. for its self-developed innovative radiopharmaceutical GPN01530 [1] - Changfeng Pharmaceutical (02652) has had its clinical trial application for Olopatadine Mometasone nasal spray accepted by NMPA [1] - CRRC (01766) and its subsidiaries have signed significant contracts totaling approximately 53.31 billion yuan over the past three months [1] - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan (00874), plans to invest around 500 million yuan to acquire 100% equity of Zhejiang Pharmaceutical Industry Co., Ltd. [1] Buybacks - China Metallurgical Group (01618) intends to repurchase up to 2 billion yuan of A-shares and 500 million yuan of H-shares [1] - Tencent Holdings (00700) repurchased 1.057 million shares for 636 million HKD on December 17 [1] - Techtronic Industries (00669) repurchased 500,000 shares for 44.91 million HKD on December 17 [1] - Country Garden Services (06098) repurchased 3.697 million shares for 23.17 million HKD on December 17 [1] - COSCO Shipping Holdings (01919) repurchased 285,750 shares for 38.61 million HKD on December 17 [1]

Group 1 - Shanghai Airport signed three duty-free store project operation rights transfer contracts with Dufour and China Duty Free Group, with no impact on current year performance but expected positive influence on revenue from 2026 to 2033 [1] - China CNR Corporation signed several major contracts totaling approximately 533.1 billion yuan, including wind power and energy storage equipment sales contracts worth about 166.5 billion yuan, which represents 21.6% of the company's projected 2024 revenue [2] - CICC is planning to absorb and merge with Dongxing Securities and Xinda Securities through a share exchange, with stock trading resuming on December 18, 2025, pending board and shareholder approvals [3] Group 2 - Xiechuang Data signed a cooperation agreement for a research and production project of optical chips and modules in Guangzhou, which is expected to positively impact future performance if successfully implemented [4] - Meike Home is planning to acquire control of Shenzhen Wandeli Optoelectronics through a combination of share issuance and cash payment, with stock suspension starting December 18, 2025 [5] - Bona Film Group is preparing multiple film and series projects, actively participating in the New Year and Spring Festival releases, while facing stock trading volatility due to a significant price drop [6] Group 3 - Tongrentang clarified that it does not hold any equity or investment rights in Sichuan Health Pharmaceutical, which is a subsidiary of its controlling shareholder, and is taking steps to address related reports [7][8] - Fengxing Co. plans to acquire 75% of Baiyin Huaxin, which is expected to constitute a major asset restructuring [9] - Deep City Transportation plans to raise no more than 1.8 billion yuan through a private placement for the development of intelligent transportation equipment [9]

Core Viewpoint - The acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. by Guangzhou Pharmaceutical is a strategic move to enhance market presence in the East China region, with a transaction value of RMB 500 million [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical, a subsidiary of the company, has entered into a share purchase agreement to acquire 100% equity of Zhejiang Pharmaceutical from Haizheng Pharmaceutical for RMB 500 million [1] - The acquisition is set to be completed by December 17, 2025, after which Guangzhou Pharmaceutical will hold full ownership of the target company [1] Group 2: Target Company Overview - Zhejiang Pharmaceutical is a leading pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1] - The company reported annual sales revenue exceeding RMB 4 billion in the past year, indicating a strong growth potential [1] Group 3: Strategic Rationale - The acquisition price reflects a premium over the assessed value, which the company considers reasonable based on several factors [1] - The target company is ranked among the top six pharmaceutical distribution enterprises in Zhejiang, providing a well-established customer network and market presence [1] - This acquisition will enable Guangzhou Pharmaceutical to optimize its industrial layout in East China and enhance coverage in the domestic terminal market [1]

白云山（600332）(00874)公布，于2025年12月17日，买方(广州医药，公司子公司)与卖方(海正药业 （600267），公司独立第三方)订立了股权交易合同及补充协议。根据股权交易合同及补充协议，买方 拟收购浙江省医药工业有限公司100%股权，收购对价为约人民币5.005亿元。于收购事项完成后，买方 将持有目标公司100%股权。 公告称，目标公司位于长三角地区，医药市场发达，是浙江省排名前六的优质医药流通企业。目标公司 长期深耕浙江省市场，积累了丰富的客户资源，最近一年年销售收入规模超过人民币40亿元，具有良好 发展前景;收购事项有利于广州医药获取浙江省及周边地区成熟的客户网络，进一步优化在华东区域的 产业佈布局，提升对国内终端市场的覆盖广度和深度。 ...

智通财经APP讯，白云山(00874)公布，于2025年12月17日，买方(广州医药，公司子公司)与卖方(海正药 业，公司独立第三方)订立了股权交易合同及补充协议。根据股权交易合同及补充协议，买方拟收购浙 江省医药工业有限公司100%股权，收购对价为约人民币5.005亿元。于收购事项完成后，买方将持有目 标公司100%股权。 公告称，目标公司位于长三角地区，医药市场发达，是浙江省排名前六的优质医药流通企业。目标公司 长期深耕浙江省市场，积累了丰富的客户资源，最近一年年销售收入规模超过人民币40亿元，具有良好 发展前景;收购事项有利于广州医药获取浙江省及周边地区成熟的客户网络，进一步优化在华东区域的 产业佈布局，提升对国内终端市场的覆盖广度和深度。 ...

Core Viewpoint - The acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. by Guangzhou Pharmaceutical is a strategic move to enhance market presence in the East China region, with a transaction value of RMB 500 million [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical, a subsidiary of the company, has entered into a share purchase agreement to acquire 100% equity of Zhejiang Pharmaceutical from Haizheng Pharmaceutical for RMB 500 million [1] - The acquisition is set to be completed by December 17, 2025, after which Guangzhou Pharmaceutical will hold full ownership of the target company [1] Group 2: Target Company Overview - Zhejiang Pharmaceutical is a leading pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1] - The company reported annual sales revenue exceeding RMB 4 billion in the past year, indicating a strong growth potential [1] Group 3: Strategic Rationale - The acquisition price reflects a premium over the assessed value, which the company considers reasonable based on several factors [1] - The target company is ranked among the top six pharmaceutical distribution enterprises in Zhejiang, providing a well-established customer network and market presence [1] - This acquisition will enable Guangzhou Pharmaceutical to optimize its industrial layout in East China and enhance coverage in the domestic terminal market [1]

Key Points - The core viewpoint of the announcements highlights various corporate activities including acquisitions, investments, and share buybacks across multiple companies in the market [1][2][3] Group 1: Corporate Activities - Tongrentang (600085.SH) does not hold any direct or indirect equity or investment rights in Sichuan Health Pharmaceutical related to Antarctic krill oil [2] - Victory Energy (001331.SZ) has no plans for a reverse merger through the listed company in the next 36 months [2] - Xiechuang Data (300857.SZ) plans to invest in the research and production of optical chips and modules [2] - Pubon Co., Ltd. (002663.SZ) has jointly won the construction project for Xiangmi Lake Park [2] - Baiyunshan (600332.SH) subsidiary Guangzhou Pharmaceutical intends to acquire 100% equity of Zhejiang Medical Engineering for 500.5 million yuan [2] Group 2: Share Buybacks and Capital Increases - China Metallurgical Group (601618.SH) plans to repurchase company shares worth between 1 billion to 2 billion yuan [2] - Shengxing Co., Ltd. (002752.SZ) intends to raise no more than 1.157 billion yuan through a private placement [3] - Shenzhen Urban Transport (301091.SZ) plans to raise no more than 1.8 billion yuan through a private placement [3] Group 3: Shareholding Changes - Sanwei Tiandi (301159.SZ) actual controller and concerted parties plan to reduce their holdings by no more than 3% [2] - Zhaobiao Co., Ltd. (301136.SZ) controlling shareholder intends to reduce holdings by no more than 3% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 須予披露交易 收購目標公司100%股權 收購事項 董事會欣然宣佈，於2025年12月17日，買方（廣州醫藥，本公司子公司）與賣方（海正藥業，本公司 獨立第三方）訂立了股權交易合同及補充協議。根據股權交易合同及補充協議，買方同意收購， 賣方同意出售目標公司100%股權，收購對價為人民幣50,050.00萬元。於收購事項完成後，買方 將持有目標公司100%股權。 香港上市規則的涵義 由於股權交易合同項下擬進行的交易之所有適用百分比率（定義見香港上市規則第14.07條）中最高 者超過5%但低於25%，該交易構成本公司一項須予披露交易，須遵守香港上市規則第14章項下的 申報及公告規定，但無須本公司股東的批准。 緒言 董事會欣然宣佈，於2025年12月17日，買方（廣州醫藥，本公司子公司）與賣方（海正藥業，本公司獨 立第三方）訂立了股權交易合同及補充協議。根據股權交易合同及補充協議內容，買方同意收購，賣 方同意出 ...